Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion.

The transaction was announced publicly in the following press release, which can be viewed here.

Lead Team: Jamie Leigh and Kevin Cooper led the Cooley team advising Neurocrine.

Supporting Team: Ryan Genkin, Nicholaus Johnson, Katie Benvenuti, Nicholas Orr, Sunny Liu, Michelle Hunt, Vittoria Rainone, Joe Perry, Matthew Scarano and Sharon Davidov provided invaluable support.

Cooley has served as Neurocrine’s primary corporate and transactional counsel for approximately 20 years. During that time, the firm has advised the company on a variety of matters, including its acquisition of Diurnal (2023) and its $517.5 million private offering of convertible senior notes (2017). Cooley has also counseled Neurocrine on numerous license agreements with leading life sciences companies, including Mitsubishi Tanabe Pharma (2015), Xenon (2019), Takeda (2020), Sosei Heptares (2021), Voyager Therapeutics (2023), and TransThera (2025).

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.